AOA2 Genetic Detection via SETX Mutation Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively distinguish ataxia-ocular apraxia 2 (AOA2) from other diseases such as autosomal dominant juvenile amyotrophic lateral sclerosis (ALS4) and ataxia with oculomotor apraxia type 1 (AOA1), necessitating a means to accurately assess genetic polymorphisms associated with AOA2.
Innovation Solution
The method involves assessing test samples for specific mutations in the senataxin (SETX) gene, including insertions, deletions, and transitions, using techniques like amplification, direct sequence analysis, and hybridization to identify genetic polymorphisms indicative of AOA2, allowing for diagnosis and carrier status determination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard genetic testing methods are used, then general genetic analysis can be performed, but the ability to distinguish AOA2 from other diseases (ALS4, AOA1) is insufficient
Solution Approach 1:
The patent segments the genetic testing process by identifying and analyzing specific mutations in the SETX gene (such as c.1634C>T, c.4873-4878del6insGG, c.6848-6851del4) that are characteristic of AOA2. This segmentation allows differentiation from ALS4 and AOA1 by focusing on disease-specific mutational patterns rather than general genetic analysis.
Solution Approach 2:
The invention applies local quality by targeting specific loci and mutation types within the SETX gene that are uniquely associated with AOA2. By analyzing particular regions (exons 10, 26, etc.) and specific mutation characteristics, the method achieves high diagnostic precision for AOA2 without requiring comprehensive analysis of the entire genome.
2Reliability
If comprehensive genetic analysis is performed to distinguish AOA2 from other diseases, then diagnostic accuracy improves, but the complexity and time required for testing increases
Solution Approach 1:
The patent employs preliminary action by first screening for specific characteristic mutations in the SETX gene that are highly indicative of AOA2 (such as the c.4873-4878del6insGG mutation). This preliminary screening allows for rapid identification of likely AOA2 cases before proceeding to more comprehensive analysis, thereby reducing overall testing time while maintaining diagnostic reliability.
Solution Approach 2:
The invention uses copying by creating specific probes and assays targeting known AOA2-associated mutations. These copied molecular patterns allow for rapid detection and comparison against reference sequences, enabling quick differentiation from ALS4 and AOA1 without requiring de novo comprehensive sequencing.
Data Source
AI summary
Methods of identifying polymorphisms associated with ataxia-ocular apraxia 2 (AOA2), are described. The polymorphisms associated with AOA2 include specific mutations in the senataxin (SETX) gene. Also described are methods of diagnosis of AOA2, as well as methods of assessing an individual for carrier status for AOA2.